A detailed history of Csenge Advisory Group transactions in Novartis Ag stock. As of the latest transaction made, Csenge Advisory Group holds 10,026 shares of NVS stock, worth $986,057. This represents 0.06% of its overall portfolio holdings.

Number of Shares
10,026
Previous 9,348 7.25%
Holding current value
$986,057
Previous $995,000 15.88%
% of portfolio
0.06%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$106.13 - $120.89 $71,956 - $81,963
678 Added 7.25%
10,026 $1.15 Million
Q2 2024

Jul 10, 2024

BUY
$92.57 - $107.37 $258,455 - $299,777
2,792 Added 42.59%
9,348 $995,000
Q1 2024

May 03, 2024

SELL
$95.27 - $108.47 $130,043 - $148,061
-1,365 Reduced 17.23%
6,556 $634,000
Q4 2023

Feb 13, 2024

BUY
$92.27 - $101.54 $74,369 - $81,841
806 Added 11.33%
7,921 $799,000
Q3 2023

Nov 01, 2023

BUY
$94.73 - $105.13 $351,353 - $389,927
3,709 Added 108.9%
7,115 $724,000
Q2 2023

Jul 20, 2023

BUY
$92.52 - $104.91 $315,123 - $357,323
3,406 New
3,406 $343,000
Q2 2021

Jul 21, 2021

SELL
$85.24 - $94.15 $197,074 - $217,674
-2,312 Closed
0 $0
Q1 2021

Apr 28, 2021

SELL
$83.5 - $98.47 $12,608 - $14,868
-151 Reduced 6.13%
2,312 $202,000
Q4 2020

Jan 26, 2021

SELL
$78.07 - $94.43 $35,053 - $42,399
-449 Reduced 15.42%
2,463 $233,000
Q3 2020

Nov 09, 2020

BUY
$82.14 - $91.0 $3,860 - $4,277
47 Added 1.64%
2,912 $252,000
Q2 2020

Jul 17, 2020

SELL
$80.93 - $91.1 $44,673 - $50,287
-552 Reduced 16.15%
2,865 $250,000
Q1 2020

Apr 21, 2020

BUY
$70.67 - $99.01 $241,479 - $338,317
3,417 New
3,417 $282,000
Q4 2018

Feb 07, 2019

SELL
$73.66 - $82.02 $1,546 - $1,722
-21 Closed
0 $0
Q3 2018

Nov 19, 2018

BUY
$66.94 - $77.43 $1,405 - $1,626
21 New
21 $1,000

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $212B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Csenge Advisory Group Portfolio

Follow Csenge Advisory Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Csenge Advisory Group, based on Form 13F filings with the SEC.

News

Stay updated on Csenge Advisory Group with notifications on news.